EMA Authorised: Skyclarys (omaveloxolone) — Biogen Netherlands B.V.

View source ↗

Summary

Authorisation of Skyclarys (omaveloxolone) for Friedreich ataxia by the EMA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• SKYCLARYS (omaveloxolone)

Snippet

Status: Authorised. Therapeutic area: Friedreich Ataxia. MAH: Biogen Netherlands B.V.. Decision date: 11/06/2026. Orphan medicine